News

BridgeBio to Showcase Heart Failure Insights at Upcoming Event

BridgeBio to Showcase Heart Failure Insights at Upcoming Event

BridgeBio Pharma's Upcoming Presentation at HFSA Meeting

BridgeBio Pharma, a pioneering company in the field of genetic diseases, is gearing up to share exciting new data at an upcoming scientific meeting. The company, known for its innovative treatments, has announced it will present compelling cardiovascular outcomes from its ATTRibute-CM study at the Heart Failure Society of America's Annual Scientific Meeting.

Overview of Presentations

This presentation will feature an assortment of formats, including one late-breaking clinical trial oral presentation, an additional oral presentation, and three poster sessions. These sessions promise to provide valuable insights into cardiovascular health, especially pertaining to transthyretin amyloidosis cardiomyopathy (ATTR-CM).

Late Breaking Clinical Trials Presentation

One of the highlights of the meeting will be the late-breaking clinical trials presentation titled Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM. This talk will be presented by Dr. Ahmad Masri of Oregon Health & Science University on Sunday morning. This analysis is anticipated to shed light on how Acoramidis impacts both recurrent and cumulative cardiovascular outcomes in patients.

Significant Oral Presentation

Additionally, on Saturday, Dr. Lily Stern from the Cedars-Sinai Heart Institute will deliver an oral presentation highlighting the pivotal findings of a study demonstrating that continuous Acoramidis treatment significantly reduces the risk of all-cause mortality and cardiovascular-related hospitalizations in patients with wild-type and variant TTR amyloidosis cardiomyopathy at 42 months.

Informative Poster Sessions

The poster sessions, scheduled for Saturday and Sunday, will further explore notable aspects of Acoramidis' therapeutic profile. One poster will delve into how Acoramidis mitigates the rise in NT-proBNP levels observed in patients undergoing treatment for variant transthyretin amyloid cardiomyopathy. Another session will discuss the effect of Acoramidis on cardiac conduction abnormalities related to this rare condition.

Investigation of State-Level Incidence

A third poster will examine state-level differences in the incidence of transthyretin amyloid cardiomyopathy in U.S. veterans, a critical topic as the understanding of this disease evolves with the introduction of new therapies.

About Acorabidis

Acorabidis (Attruby™) is a transthyretin stabilizer indicated for treating the cardiomyopathy of both wild-type and variant transthyretin-mediated amyloidosis (ATTR-CM) in adults. This treatment is focused on reducing cardiovascular deaths and hospitalizations related to cardiovascular issues.

Safety Information

While Acorabidis has shown promising results, it's essential to be aware of the safety information regarding its use. Adverse reactions primarily include diarrhea and upper abdominal pain, which were mostly mild and resolve without discontinuation of the medication. Comparative discontinuation rates for both Acorabidis and placebo treatments were similar.

About BridgeBio Pharma

Founded in 2015, BridgeBio Pharma is dedicated to discovering and delivering transformative medicines for patients affected by genetic diseases. The company's mission is to apply genetic medicine advances rapidly to enhance patient care. With a stable pipeline encompassing various stages of development from early science to advanced clinical trials, BridgeBio is poised to make a significant impact in the life sciences arena.

Contact Information

For Media Inquiries:
Bubba Murarka, Executive Vice President, Corporate Development
Email: contact@bridgebio.com
Phone: (650)-789-8220

For Investor Relations:
Chinmay Shukla, Senior Vice President, Strategic Finance
Email: ir@bridgebio.com

Frequently Asked Questions

What is the focus of BridgeBio Pharma?

BridgeBio Pharma specializes in the treatment of genetic diseases through innovative biopharmaceutical solutions.

What will BridgeBio present at the HFSA Annual Meeting?

They will present new cardiovascular outcomes data from the ATTRibute-CM study on treatments for transthyretin amyloidosis cardiomyopathy.

Who are the presenters for the late-breaking clinical trials?

The late-breaking presentation will be led by Dr. Ahmad Masri from Oregon Health & Science University.

What safety information should patients be aware of regarding Acorabidis?

Common adverse reactions include diarrhea and abdominal pain, mostly mild and manageable without treatment cancellation.

When was BridgeBio Pharma founded?

BridgeBio Pharma was established in 2015 and has since been focused on addressing genetic diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Deadline Looms for EquipmentShare Investors' Legal Action

Updated Category News Views 1

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

Continue Reading
Cannabis Industry Pushes for Robust Financial Services

Updated Category News Views 3

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Continue Reading
Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 1

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
Helio Fred Garcia Honored by Diversity Action Alliance

Updated Category News Views 1

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Continue Reading
WNET's 25th Anniversary 9/11 Tribute: Stories and Lessons

Updated Category News Views 3

Reflecting on a Dark Day with WNET's Programming Nothing quite hits you like the anniversary of a colossal tragedy. The memories of September 11, 2001, remain etched in the urban landscape of New York City, and this year marks 25 years since that heart-wrenching day. The WNET Group steps up to the plate with a comprehensive slate of programming aimed at honoring the...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 2

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading
Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Updated Category News Views 3

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Continue Reading
Navigating Land Access: The Hidden Roadblock in Mining

Updated Category News Views 1

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 1

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 1

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading

Top 5 Most Recently Viewed Articles

Stuart Therapeutics Reveals Promising Phase III Results for ST-100

Updated Category News Views 111

Exciting Developments from Stuart Therapeutics Stuart Therapeutics is making waves in the ophthalmology field with their latest announcement concerning ST-100, also known as Vezocolmitide. This innovative ophthalmic solution is under investigation as a potential treatment for dry eye disease, a condition that affects millions of individuals worldwide. The extensive...

Continue Reading
Suunto's Innovative Race 2 Watch and Wing 2 Headphones Launch

Updated Category News Views 235

Suunto Unveils Race 2 Watch and Wing 2 Headphones Suunto, a leader in sports technology, has just introduced two exciting products aimed at enhancing the experiences of runners and fitness enthusiasts: the Suunto Race 2 trail running watch and the Wing 2 bone conduction headphones. These innovative devices are set to redefine performance, comfort, and safety, helping...

Continue Reading
Capgemini’s Insights on Energy Transition Challenges

Updated Category News Views 121

Capgemini’s World Energy Markets Observatory Annual Report Highlights The latest edition of Capgemini’s World Energy Markets Observatory (WEMO) reveals critical insights regarding the challenges faced in the global energy sector. Although there have been notable improvements in renewable energy development, the report underscores that the pace remains insufficient....

Continue Reading
Earnings Forecast for Interactive Brokers Group: What to Expect

Updated Category News Views 294

Anticipated Earnings from Interactive Brokers Group Interactive Brokers Gr (NASDAQ: IBKR) is scheduled to announce its quarterly earnings soon, and expectations are running high among investors. Analysts have estimated an earnings per share (EPS) of $0.52, a significant figure that could influence stock performance post-announcement. Earnings Expectations and Market...

Continue Reading
China's Commitment to Cultural Heritage Preservation Today

Updated Category News Views 278

In a world where rapid change is the norm, China’s commitment to cultural heritage preservation stands out. This isn’t just about keeping the past alive; it’s about safeguarding a legacy that stretches back thousands of years. Take the Mogao Grottoes near Dunhuang, for example. These caves aren’t just historical sites; they’re treasure troves of Buddhist art and...

Continue Reading